NM8074

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
50Dermatomyositis1
62Paroxysmal nocturnal hemoglobinuria3
66IgA nephropathy1
IDDisease name (Link within this page)Number of trials
109Atypical hemolytic uremic syndrome1
223Primary membranoproliferative glomerulonephritis1

50. Dermatomyositis


Clinical trials : 264 / Drugs : 298 - (DrugBank : 66) / Drug target genes : 71 - Drug target pathways : 173 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

62. Paroxysmal nocturnal hemoglobinuria


Clinical trials : 380 / Drugs : 240 - (DrugBank : 38) / Drug target genes : 28 - Drug target pathways : 122 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

66. IgA nephropathy


Clinical trials : 407 / Drugs : 342 - (DrugBank : 73) / Drug target genes : 40 - Drug target pathways : 146 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

109. Atypical hemolytic uremic syndrome


Clinical trials : 130 / Drugs : 44 - (DrugBank : 5) / Drug target genes : 2 - Drug target pathways : 11 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

223. Primary membranoproliferative glomerulonephritis


Clinical trials : 243 / Drugs : 296 - (DrugBank : 84) / Drug target genes : 46 - Drug target pathways : 169 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries